Screener
Roivant Sciences ROIV Business Segments — Acquired in-process research and development
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Roivant Sciences in its filing.
Tagged under the XBRL concept roiv:AcquiredInProcessResearchAndDevelopmentExpense.
The source filing: Roivant Sciences’s 10-K, filed May 20, 2026.
- Filed
- May 20, 2026, 7:17 AM EDT
- Fiscal year
- FY2025
- Accession
- 0001635088-26-000061
| Line item | Years Ended March 31, 2026 | Years Ended March 31, 2025 | Years Ended March 31, 2024 |
|---|---|---|---|
| Operating expenses: | |||
| Cost of revenues | 1,285 | 911 | 1,599 |
| Research and development (includes $47,867, $39,780 and $32,400 of share-based compensation expense for the years ended March 31, 2026, 2025 and 2024, respectively) | 681,812 | 550,413 | 439,909 |
| Acquired in-process research and development | — | — | 26,450 |
| General and administrative (includes $298,298, $239,505 and $154,873 of share-based compensation expense for the years ended March 31, 2026, 2025 and 2024, respectively) | 610,466 | 591,410 | 416,133 |
| Total operating expenses | 1,293,563 | 1,142,734 | 884,091 |
| Gain on sale of Telavant net assets | — | 110,387 | 5,348,410 |
| Gain on litigation settlement | 770,235 | — | — |
ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA
FAQ
- What is Roivant Sciences's business segments — acquired in-process research and development?
- Roivant Sciences (ROIV) reported business segments — acquired in-process research and development of $0 in Q1 2026.
- What is the long-term trend for Roivant Sciences's business segments — acquired in-process research and development?
- Over 2 years (2023 to 2025), Roivant Sciences's business segments — acquired in-process research and development has grown at a -100.0% compound annual growth rate (CAGR), from $26.45M to $0.
- What does business segments — acquired in-process research and development mean?
- This represents the value assigned to research and development projects acquired through business combinations that have not yet reached technological feasibility. It reflects the capital allocated to external innovation pipelines that are integrated into the company's existing research framework. These costs are typically expensed immediately upon acquisition under accounting standards for R&D assets.
Ask your AI about Roivant Sciences's business segments — acquired in-process research and development.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude